Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
10.1007/s11596-015-1466-6
- Author:
Bin-Yong LIANG
1
;
Min XIONG
;
Gui-Bao JI
;
Er-Lei ZHANG
;
Zun-Yi ZHANG
;
Ke-Shuai DONG
;
Xiao-Ping CHEN
;
Zhi-Yong HUANG
Author Information
1. Research Laboratory and Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China, liangby2015@163.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Drug Synergism;
Hep G2 Cells;
Histone Deacetylase Inhibitors;
administration & dosage;
pharmacology;
Humans;
Hydroxamic Acids;
administration & dosage;
pharmacology;
Liver Neoplasms;
drug therapy;
Mice;
Phenanthrenes;
administration & dosage;
pharmacology;
Poly(ADP-ribose) Polymerase Inhibitors;
administration & dosage;
pharmacology;
Xenograft Model Antitumor Assays
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(4):535-540
- CountryChina
- Language:English
-
Abstract:
Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and histone deacetylase (HDAC) inhibitors have recently emerged as promising anticancer drugs. The aim of this study was to investigate the effect of combination treatment with the PARP inhibitor PJ34 and HDAC inhibitor SAHA on the proliferation of liver cancer cells. Cell proliferation and apoptosis were assessed in three human liver cancer cell lines (HepG2, Hep3B and HCC-LM3) treated with PJ34 (8 μmol/L) and SAHA (1 μmol/L), alone or combined, by Cell Counting Kit-8 assay and flow cytometry, respectively. The nude mice bearing subcutaneous HepG2 tumors were administered different groups of drugs (10 mg/kg PJ34, 25 mg/kg SAHA, 10 mg/kg PJ34+25 mg/kg SAHA), and the inhibition rates of tumor growth were compared between groups. The results showed that combined use of PJ34 and SAHA could synergistically inhibit the proliferation of liver cancer cell lines HepG2, Hep3B and HCC-LM3. The apoptosis rate of HepG2 cells treated with PJ34+SAHA was significantly higher than that of HepG2 cells treated with PJ34 or SAHA alone (P<0.05). In vivo, the tumor inhibition rates were 53.5%, 61.4% and 82.6% in PJ34, SAHA and PJ34+SAHA groups, respectively. The combined use of PJ34 and SAHA could significantly inhibit the xenograft tumor growth when compared with use of PJ34 or SAHA alone (P<0.05). It was led to conclude that PJ34 and SAHA can synergistically suppress the proliferation of liver cancer cells.
